Why is Mangalam Drugs falling/rising?

As of 09-Jul, Mangalam Drugs and Organics Ltd is experiencing a price increase, currently at Rs 91.00, reflecting a rise of Rs 3.8 or 4.36%. The stock has shown strong performance recently, gaining 15.15% over the last nine days and outperforming its sector by 4.16% today. It reached an intraday high of Rs 94, indicating significant investor interest. Despite a year-to-date decline of 21.52%, the stock's profits have surged by 176.5%, leading to a very attractive valuation with a low PEG ratio of 0.1. However, the company faces challenges such as a high Debt to EBITDA ratio and a recent sharp decline in quarterly PAT, which may temper investor enthusiasm.
In the broader market context, the stock's short-term performance of +9.32% over the past week significantly outpaces the Sensex, which has only increased by 0.15%. This suggests that while Mangalam Drugs is gaining traction in the short term, it has consistently underperformed against broader benchmarks over the last three years. The stock's current liquidity and rising investor participation may indicate a shift in sentiment, but the long-term fundamentals remain weak, as evidenced by a low average Return on Equity and a modest CAGR growth in operating profits over the past five years.